Last reviewed · How we verify
GNbAC1
GNbAC1 is a recombinant immunoglobulin targeting the human immunoglobulin G1 (IgG1) Fc region.
GNbAC1 is a recombinant immunoglobulin targeting the human immunoglobulin G1 (IgG1) Fc region. Used for Multiple sclerosis.
At a glance
| Generic name | GNbAC1 |
|---|---|
| Sponsor | GeNeuro Innovation SAS |
| Drug class | Fc receptor antagonist |
| Target | Fc region of IgG1 |
| Modality | Biologic |
| Therapeutic area | Autoimmune diseases |
| Phase | Phase 2 |
Mechanism of action
GNbAC1 works by binding to the Fc region of IgG1 antibodies, thereby preventing their interaction with Fc receptors on immune cells. This mechanism of action is thought to modulate the immune response and potentially reduce inflammation and autoimmune disease activity.
Approved indications
- Multiple sclerosis
Common side effects
- Injection site reactions
- Headache
- Fatigue
Key clinical trials
- Clinical Trial Assessing Temelimab Following Rituximab Treatment in Patients With Relapsing Forms of Multiple Sclerosis (PHASE2)
- Temelimab as a Disease Modifying Therapy in Patients With Neuropsychiatric Symptoms in Post-COVID 19 or PASC Syndrome (PHASE2)
- A Long-term Extension of Study GNC-401 (PHASE2)
- Safety Study of GNbAC1 in Multiple Sclerosis Patients (PHASE2)
- Safety Study of GNbAC1 Monoclonal Antibody in Healthy Male Volunteers (PHASE1)
- Single Ascending Doses Study With GNbAC1 in Healthy Male Volunteers (PHASE1)
- First-in-Human Study With GNbAC1 in Healthy Volunteers (PHASE1)
- Clinical Trial Assessing the GNbAC1 in Patients With Onset of Type 1 Diabetes Within 4 Years (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GNbAC1 CI brief — competitive landscape report
- GNbAC1 updates RSS · CI watch RSS
- GeNeuro Innovation SAS portfolio CI